8-K/A: Silexion Therapeutics Amends Nasdaq Listing Compliance Timeline, Confirms Reverse Stock Split Plan

Silexion Therapeutics Corp. filed an amendment to its 8-K report, updating the expected timing for its transfer to the Nasdaq Capital Market and its plan to regain minimum bid price compliance through a 1-for-15 reverse share split.

Summary

• Silexion Therapeutics Corp. (SLXN) filed an Amendment No. 1 to its Current Report on Form 8-K to update and correct expected timing related to its Nasdaq listing status.
• A Nasdaq hearings panel granted the Company's request to remain listed on Nasdaq, subject to certain conditions.
• The Company's ordinary shares and warrants will be transferred from the Nasdaq Global Market to the Nasdaq Capital Market, expected to be effected by Nasdaq as soon as practicable, not necessarily on July 8, 2025 as previously reported.
• Silexion may soon become deficient with Nasdaq Listing Rule 5550(a)(2) if its ordinary shares close below $1.00 for 30 consecutive trading days.
• To remedy this potential deficiency, the Company plans a 1-for-15 reverse share split.
• Shareholder approval for the reverse share split is anticipated at the reconvened 2025 annual general meeting on July 14, 2025.
• Following shareholder approval, a required 10-day Nasdaq notice period must conclude, expected on or about July 25, 2025.
• The 10-day trading period for the share price to remain above $1.00 after the reverse split is expected to conclude in early to mid-August 2025, at which point the Company expects to regain compliance.

Sentiment

Score: 3

Explanation: The sentiment is negative. While the company avoided immediate delisting, it is being moved to a lower-tier market and is undertaking a reverse stock split, which are generally signs of distress. The delays in compliance timeline further add to the negative sentiment. The primary positive is avoiding immediate delisting, but the underlying issues remain.

Positives

• Nasdaq hearings panel granted the Company's request to remain listed on Nasdaq, avoiding immediate delisting.

Negatives

• The Company's listing will be transferred to the Nasdaq Capital Market, often perceived as a less prestigious market than the Nasdaq Global Market.
• Silexion is facing a potential minimum bid price deficiency, indicating its share price has been trading below $1.00.
• A 1-for-15 reverse share split is planned, which often signals financial distress and can be viewed negatively by investors.
• The expected timing for regaining compliance has been delayed from previous estimates.

Risks

• There is no assurance that Silexion will successfully meet the terms of its compliance plan.
• There is no assurance that Silexion will maintain compliance with all relevant standards for maintaining its listing on the Nasdaq Capital Market.
• The Company's shareholders may not approve the proposed 1-for-15 reverse share split at the upcoming annual general meeting on July 14, 2025.
• Actual future events could differ materially from forward-looking statements due to various factors, including the risk of shareholder non-approval.

Future Outlook

The Company anticipates shareholder approval for a 1-for-15 reverse share split at its July 14, 2025 annual general meeting. Following this, and a subsequent 10-day Nasdaq notice period, the Company expects to achieve and maintain a minimum bid price of at least $1.00 for 10 consecutive trading days, with compliance expected to be regained in early to mid-August 2025. However, there is no assurance that these expectations will be met.

Management Comments

• "The Company anticipates [shareholder approval for the reverse share split] will occur pursuant to Proposal 3 at the Company's 2025 annual general meeting that is scheduled to reconvene on July 14, 2025."
• "[The Company] would only expect to have regained compliance with that potential minimum bid price deficiency [in early to mid-August 2025]."

Industry Context

This announcement primarily concerns Silexion's specific corporate governance and listing compliance issues rather than broader industry trends. Companies in the biotechnology or pharmaceutical sector, especially smaller ones, can frequently face challenges in maintaining stock exchange listing requirements, particularly minimum bid price rules, due to volatile stock performance or lack of significant revenue streams.

Comparison to Industry Standards

• Many small-cap biotechnology and pharmaceutical companies listed on Nasdaq face similar challenges with maintaining minimum bid price requirements, often resorting to reverse stock splits to avoid delisting. For example, companies like Sorrento Therapeutics (SRNEQ) or Athersys (ATHX) have undergone reverse splits or faced delisting notices due to share price issues.
• The transfer from Nasdaq Global Market to Nasdaq Capital Market is a common step for companies that no longer meet the more stringent listing requirements of the Global Market, indicating a downgrade in listing tier, similar to moves seen with companies like Biocept (BIOC) or Evoke Pharma (EVOK) in the past when facing compliance issues.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential dilution effect from the reverse split (though not directly dilutive, it reduces the number of shares held), potential negative perception due to the need for a reverse split and market transfer, and uncertainty regarding continued Nasdaq listing compliance.
• Investors: Increased risk due to the Company's struggle to maintain listing requirements and the inherent volatility associated with companies undergoing reverse splits and market transfers.

Next Steps

• Shareholder vote on the 1-for-15 reverse share split at the reconvened 2025 annual general meeting on July 14, 2025.
• Completion of a 10-day Nasdaq notice period following shareholder approval of the reverse share split (expected on or about July 25, 2025).
• Achieving a closing bid price above $1.00 for 10 consecutive trading days after the reverse share split (expected to conclude in early to mid-August 2025).

Key Dates

Recommendation

Keywords

Silexion Therapeutics, SLXN, Nasdaq, Listing Compliance, Reverse Share Split, Minimum Bid Price, Delisting, 8-K/A, Corporate Governance, Shareholder Meeting